Sign In
By signing in or creating an account, you agree with Associated Broadcasting Company's Terms & Conditions and Privacy Policy.
By signing in or creating an account, you agree with Associated Broadcasting Company's Terms & Conditions and Privacy Policy.
NephroPlus IPO files papers with SEBI; company aims to raise to Rs 353.4 crore
New Delhi: Nephrocare Health Services, popularly known as Nephro Plus due to its trusted dialysis services, is all set for its public debut in the market as per the information obtained from its DRHP. The IPO is worth Rs 353 crore of a fresh issue of equity shares and an additional component of offer-for-sale (OFS) of shares by its existing promoters and shareholders. In this regard, the company has filed its paper with the market regulator SEBI, seeking its approval.
The OFS part includes promoters offloading their 1.27 crore shares. Promoters like Investcorp Private Equity Fund II, Healthcare Parent Ltd, Investcorp Growth Opportunity Fund, and Edoras Investment Holdings Pte Ltd will be selling their existing shares.
Additionally, other shareholders like Investcorp India Private Equity Opportunity Ltd., International Finance Corporation, 360 One Special Opportunities Fund - Series 9, and 360 One Special Opportunities Fund - Series 10 are set to offload their sale.
The company aims to utilize the raised capital from the IPO for enhancing its infrastructure in India. Out of total proceeds of Rs 353 crore, a section worth Rs 129 crore is set to be used by the company for opening new clinics across India. The remaining amount, Rs 136 crore, will be set aside for the payment of debt, and the rest will be used for general corporate purposes.
There exist plans for pre-IPO placement of Rs 70.6 crore on the company's part. In such a case, the fresh issue will get adjusted with the pre-IPO placement amount.
The company was founded in 2009 and is a trusted dialysis services provider in the country. The company spans 447 clinics across 269 cities in 21 states and 4 union territories. The company serves more than 33,000 patients globally on a yearly basis. The company has expanded its presence and has an international reach in several countries, like the Philippines (34 clinics), Uzbekistan (4 clinics), and Nepal (5 clinics). The company recently entered the Middle East market by opening a clinic in Saudi Arabia.
As of March 31, 2025, NephroPlus had more than 5,000 dialysis machines and performed over 3.3 million treatments.
In FY25, NephroPlus posted an operating revenue of Rs 755.8 crore and a net profit of Rs 67 crore.
For its upcoming IPO, the company has roped in ICICI Securities, Ambit, IIFL Capital Services, and Nomura Financial Advisory and Securities (India) as book-running lead managers.
(Disclaimer: This article is only meant to provide information. TV9 does not recommend buying or selling shares or subscriptions of any IPO, Mutual Funds, gold and crypto assets.)
